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Abstract
Background: The distribution of take-home naloxone (THN) kits has been an important strategy in reducing overdose
fatalities among people who use drugs. However, little is known about the use of THN among youth who
are street-involved. The present study explores knowledge and possession of THN among street-involved youth in a
Canadian setting.
Methods: Data were derived from the At-Risk Youth Study (ARYS), a prospective cohort of street-involved youth age
14–28 at enrollment in Vancouver, Canada. Participants completed a standardized questionnaire, which included items
related to knowledge and possession of THN, sociodemographic characteristics, and substance use-related factors.
Multivariable logistic regression models were used to identify factors independently associated with knowledge and
possession of THN.
Results: Between December 2014 and November 2016, 177 youth were interviewed, including 68 females (38.4%).
While 126 (71.2%) participants reported knowledge of THN, only 40 (22.6%) possessed a THN kit. Caucasian/white
ethnicity was found to be positively associated with both knowledge and possession of THN (both p < 0.05). Public
injection drug use in the last 6 months was found to be positively associated with knowledge of THN, while daily
heroin use and daily methamphetamine use were associated with possession of THN (all p < 0.05). Male gender was
negatively associated with possession of THN (p < 0.05).
Conclusions: These findings highlight important gaps between knowledge and possession of THN among youth and
the need to increase participation in THN programs among specific populations including non-white and male youth.
Further research is needed to gain a better understanding of the barriers that may prevent certain youth from acquiring
THN kits.
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Background
North America is in the midst of an escalating overdose
epidemic. Increases in overdose deaths have been driven
by both prescription and non-prescription opioids in the
past two decades, with a 200% increase in the rate of
opioid-related overdose deaths reported in the United
States (U.S.) since the year 2000 [1]. In British Columbia
(B.C.), illicit drug overdose deaths increased by 49%
from 2016 to September 2017, and many of these deaths
involved opioids [2]. In addition, the rate of overdose
deaths involving synthetic opioids other than metha-
done, such as fentanyl, increased by 80% from 2013 to
2014 in the U.S. [1]. Fentanyl was detected in 68% of
illicit drug overdose deaths in 2016 in B.C., and these
rates are increasing: preliminary data suggests that the
proportion of illicit drug overdose deaths for which fen-
tanyl was detected was 83% from January to September
2017 [2]. Opioid use is also a concern among youth:
while there is little national Canadian data on opioid use
among youth, one study using survey data from a
nationally representative sample of youth aged 10–18 in
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the U.S. found the 30-day prevalence of opioid use to be
4.8% from 2008 to 2011 [3].
Take-home naloxone (THN) programs, such as B.C.’s
Take Home Naloxone program [4] and the Overdose
Education and Nasal Naloxone Distribution program
(OEND) in Massachusetts [5], have been important strat-
egies in reducing overdose deaths among persons who use
drugs. Naloxone is an opioid antagonist used to temporar-
ily reverse the effects of an overdose [6]. Naloxone distri-
bution programs provide participants with naloxone in a
packaged kit and also provide training on how to recognize
and respond to an opioid-related overdose, including
administration of naloxone [6]. In 2016, THN programs
were operational in seven of Canada’s 13 provinces and
territories [6]. Similar programs have also been imple-
mented in Asia, Australia, Europe, and the U.S. [7]. A
recent systematic review suggested that THN programs
are effective in reducing overdose mortality rates in pro-
gram participants and in the community [8], with little risk
involved in its administration [9]. However, there is
evidence that younger people who use drugs (PWUD) are
less likely to access harm reduction services than older
PWUD [10–12], which raises concerns about the uptake of
THN among youth.
Previous studies have evaluated THN program imple-
mentation in various settings [13–15]. One study examin-
ing the perceptions of homeless and precariously housed
youth regarding the THN program in Vancouver, B.C.,
found that participants reported positive experiences with
THN programs—such as increased sense of safety and im-
proved self-esteem—and expressed the importance of
increasing access to THN programs [16]. In addition, in a
1999 study assessing the possible impact and acceptability
of a THN program in South London, 89% of participants
who had witnessed an overdose fatality reported that they
would have administered naloxone if it had been available
[17]. However, to our knowledge, there have been no
quantitative reports of participation rates in THN pro-
grams, or of the factors associated with participation,
among youth who are street-involved.
Drawing on a prospective cohort study of street-
involved youth in a Canadian setting, we undertook the
present study to identify sociodemographic and substance
use-related factors associated with knowledge and posses-
sion of THN among street-involved youth in Vancouver,
B.C. Vancouver is home to one of Canada’s largest and
longest operational provincial THN programs: the pro-
gram was launched in 2012 and has since distributed
over 54,000 kits, with a significant increase in distribu-
tion since 2016 (from 3394 kits in 2015 to 22,494 kits in
2016) [4]. B.C.’s THN program targets people who are at
risk of an opioid overdose and people who are likely to
witness and respond to an overdose (e.g., family or
friend of someone at risk) [4].
Methods
The At-Risk Youth Study (ARYS) is an open prospective
cohort study of street-involved youth who use illicit
drugs based in Vancouver, Canada. Youth aged 14–28
who have used any illicit drug (other than or in addition
to cannabis) in the preceding 30 days are eligible for
study enrollment. Recruited youth are street-involved at
baseline, defined as having been without stable housing
or having accessed street-based services in the preceding
6 months [18–20]. Street-based outreach is used to
enhance study recruitment both during daytime and
nighttime hours in a range of neighborhoods throughout
Vancouver where street youth are known to congregate.
Snowball sampling is also used to maximize study
enrollment. After providing informed consent, partici-
pants complete an interviewer-administered question-
naire regarding sociodemographic and socioeconomic
details, engagement with health and social services, sub-
stance use patterns, and other behavioral data. All partici-
pants are provided with monetary compensation for their
time ($30 CAN). ARYS is approved by the University of
British Columbia and Providence Health Care Research
Ethics Board. The study has been described in more detail
in previous publications [21].
Questions regarding THN were added to the cohort
questionnaire in December 2014. The present analysis
draws on baseline data from all ARYS participants who
completed a study visit between December 2014 and
November 2016. Knowledge and possession of THN
were the main outcomes of interest and were ascertained
through the following questions: “Have you heard about
a take-home Narcan rescue kit that you can keep with
you for an opiate overdose?” and “Do you currently own
a take-home Narcan rescue kit?” Individuals who
responded “yes” versus “no” to these questions were
compared using logistic regression as described below.
Explanatory variables of interest were chosen a priori
based on what we hypothesized might increase aware-
ness and possession of THN. We examined the follow-
ing explanatory variables: age (continuous, per year
older), gender (male vs. female); residing in Vancouver’s
Downtown Eastside (DTES) neighborhood in the last
6 months [a district with an open drug market as well as
high levels of substance use, poverty, and homelessness]
(yes vs. no); ever absolutely homeless (yes vs. no); educa-
tion status (high school or greater vs. other); employ-
ment in the last 6 months (yes vs. no); daily heroin use
in the last 6 months (yes vs. no); daily methampheta-
mine use in the last 6 months (yes vs. no); daily prescrip-
tion opioid use in the last 6 months (yes vs. no); daily
cocaine or crack use in the last 6 months (yes vs. no);
public injection drug use in the last 6 months (yes vs.
no); ever non-fatal overdosed [negative reaction from
using too much drugs] (yes vs. no); incarceration in the
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last 6 months, defined as being in detention, prison, or
jail overnight or longer (yes vs. no); unable to access
addiction treatment, defined as responding affirmatively
to the question: “In the past 6 months, have you tried to
access any treatment program but were unable?” (yes vs.
no); currently in methadone/methadose treatment (yes
vs. no); and been in alcohol or drug treatment in last
6 months (yes vs. no).
Initially, we examined the descriptive characteristics,
stratified by our two outcomes of interest (i.e., knowledge
and possession of THN) at the first study visit. Next, we
examined the bivariable associations between each
explanatory variable and our two outcomes of interest
using logistic regression. As a last step, we fitted multivari-
able models, considering all variables in bivariable analyses
as the full model. All statistical analyses were performed
using R, version 3.2.4 (R Foundation for Statistical
Computing, Vienna, Austria). All p values were two-sided,
and tests were considered significant at p < 0.05 level.
Results
Between December 2014 and November 2016, a total of
177 participants completed a baseline survey: 3 (1.7%)
completed a survey in 2014, 60 (33.9%) completed a sur-
vey in 2015, and 114 (64.4%) completed a survey in
2016. Among this sample, 68 (38.4%) identified as
female, 97 (54.8%) identified as Caucasian/white, and the
median age was 22.1 years (inter-quartile range [IQR] =
20.2–23.4 years). Overdose was common in our study
sample, with 81 (45.8%) participants having ever experi-
enced a non-fatal overdose.
Table 1 reports baseline characteristics of all partici-
pants stratified by our two main outcomes of interest.
As shown, 126 (71.2%) study participants reported
knowledge of THN, while 40 (22.6%) reported posses-
sion of a THN kit. In addition, when stratified by year,
34 participants (54%) reported knowledge of THN in
2014 and 2015 (combined), while 92 participants (80.7%)
reported knowledge of THN in 2016. Six participants
(9.5%) reported possession of THN in 2014 and 2015
(combined), while 34 participants (29.8%) reported
ownership of THN in 2016.
Table 2 shows the results of the bivariable and multi-
variable analyses for knowledge of THN. In bivariable
analyses, factors positively associated with knowledge of
THN included Caucasian/white ethnicity, ever homeless,
daily heroin use, public injection drug use, recent en-
gagement in drug or alcohol treatment, and inability to
access addiction treatment. Daily cocaine or crack use
was negatively associated with knowledge of THN. In
multivariable analyses, Caucasian/white ethnicity
(adjusted odds ratio [AOR] = 2.36, 95% confidence
Table 1 Baseline characteristics of 177 street-involved youth, stratified by knowledge and possession of THN
Knowledge of THN Possession of THN
Characteristic Yes (%)
n = 126
No (%)
n = 51
Yes (%)
n = 40
No (%)
n = 137
Sociodemographic characteristics
Median age (Q1–Q3)a 22.2 (20.2–23.4) 21.9 (19.6–23.4) 22.1 (20.1–23.7) 22.1 (20.2–23.4)
Male gender 73 (57.9) 36 (70.6) 15 (37.5) 94 (68.6)
White ethnicity 78 (61.9) 19 (37.3) 29 (72.5) 68 (49.6)
Downtown Eastside residenceb 33 (26.2) 14 (27.5) 8 (20.0) 39 (28.5)
Ever absolutely homeless 116 (92.1) 41 (80.4) 36 (90.0) 121 (88.3)
High school completion 58 (46.0) 26 (51.0) 20 (50.0) 64 (46.7)
Employmentb 29 (23.0) 14 (27.5) 10 (25.0) 33 (24.1)
Incarcerationb 22 (17.5) 4 (7.8) 6 (15.0) 20 (14.6)
Substance use-related factors
Daily heroin useb 44 (34.9) 6 (11.8) 20 (50.0) 30 (21.9)
Daily cocaine or crack useb 4 (3.2) 6 (11.8) 1 (2.5) 9 (6.6)
Daily methamphetamine useb 37 (29.4) 12 (23.5) 17 (42.5) 32 (23.4)
Daily use of prescription opioidsb 10 (7.9) 2 (3.9) 1 (2.5) 11 (8.0)
Public injectingb 61 (48.4) 7 (13.7) 22 (55.0) 46 (33.6)
Ever overdosed 61 (48.4) 20 (39.2) 20 (50.0) 61 (44.5)
Drug or alcohol treatmentb 77 (61.1) 22 (43.1) 27 (67.5) 72 (52.6)
Unable to access addiction treatmentb 28 (22.2) 4 (7.8) 7 (17.5) 25 (18.2)
aQ1–Q3 = 25th–75th percentiles
bIn the last 6 months
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interval [CI] 1.02–5.61) and public injection drug use
(AOR = 5.61, 95% CI 1.90–19.12) remained independ-
ently positively associated with knowledge of THN. Daily
cocaine or crack use (AOR = 0.09, 95% CI 0.01–0.59)
remained independently negatively associated with
knowledge of THN.
Table 3 shows the results of the bivariable and multi-
variable analyses for possession of THN. In bivariable
analyses, factors positively associated with possession of
THN included: Caucasian/white ethnicity; daily heroin
use; daily methamphetamine use; and public injection
drug use. Male gender was negatively associated with
possession of THN. In multivariable analyses,
Caucasian/white ethnicity (AOR = 2.51, 95% CI
1.02–6.51), daily heroin use (AOR= 3.08, 95% CI
1.09–9.11), and daily methamphetamine use (AOR= 2.99,
95% CI 1.13–8.13) remained independently positively
associated with possession of THN. Male gender (AOR =
0.29, 95% CI 0.11–0.72) remained independently negatively
associated with possession of THN.
Discussion
In the present study of street-involved youth, we ob-
served an important gap between reported knowledge of
THN programs and reported possession of THN kits.
We also found an increase in the rates of both know-
ledge and possession of THN that parallels the increase
in THN distribution that occurred in 2016. Caucasian/
white ethnicity was the only variable found to be inde-
pendently positively associated with both knowledge and
ownership of THN. Public injection drug use was inde-
pendently positively associated with THN knowledge,
while daily cocaine or crack use was independently nega-
tively associated with THN knowledge. In addition, daily
heroin and methamphetamine use were independently
positively associated with THN ownership, while male
gender was independently negatively associated with
THN ownership.
Our findings build on a qualitative study conducted in
Vancouver, B.C., which found THN programs to be
generally well-received among street-involved youth,
though the study did not assess rates of uptake in this
population [16]. Our findings also build on previous stud-
ies that have examined knowledge of and participation in
THN programs among PWUD [8, 22]. One recent study
examining THN participation among adult PWUD in
Vancouver, B.C., also identified an alarming gap between
the rates of knowledge and possession of THN [22]. One
likely explanation for this gap is an underestimation of
overdose risk (both personal and witnessed) among
PWUD. There is in fact evidence that PWUD are likely to
underestimate their own risk of opioid overdose [23],
which has been identified as a major barrier to THN own-
ership among adult PWUD [22]. Interestingly, one study
in the U.S. found that people who use opioids reported
their desire to help an overdosing peer to be a bigger
motivation for THN enrollment than a fear of personal
Table 2 Bivariate and multivariate logistic regression analyses of factors associated with knowledge of THN
Characteristics Unadjusted Adjusted
Odds ratio
(95% CI)
p value Odds ratio
(95% CI)
p value
Age (per year younger) 1.06 (0.94–1.20) 0.352 1.05 (0.88–1.26) 0.587
Gender (male vs. female) 0.57 (0.28–1.14) 0.119 0.61 (0.24–1.49) 0.283
White ethnicity (yes vs. no) 2.74 (1.41–5.43) 0.003 2.36 (1.02–5.61) 0.047
Downtown Eastside residencea (yes vs. no) 0.94 (0.46–1.99) 0.863 0.43 (0.15–1.19) 0.108
Ever homeless (yes vs. no) 2.83 (1.09–7.38) 0.031 1.99 (0.54–7.34) 0.297
High school completion (yes vs. no) 0.82 (0.43–1.57) 0.551 0.94 (0.40–2.20) 0.883
Employmenta (yes vs. no) 0.79 (0.38–1.69) 0.534 0.91 (0.36–2.37) 0.842
Incarcerationa (yes vs. no) 2.43 (0.87–8.67) 0.120 1.84 (0.50–8.08) 0.380
Daily heroin usea (yes vs. no) 4.02 (1.70–11.17) 0.003 2.37 (0.73–9.03) 1.171
Daily cocaine or crack usea (yes vs. no) 0.25 (0.06–0.90) 0.036 0.09 (0.01–0.59) 0.016
Daily methamphetamine usea (yes vs. no) 1.35 (0.65–2.95) 0.433 0.70 (0.26–1.90) 0.477
Daily use of prescription opioidsa (yes vs. no) 2.11 (0.53–14.07) 0.346 1.38 (0.17–18.75) 0.784
Public injectinga (yes vs. no) 6.09 (2.69–15.72) < 0.001 5.61 (1.90–19.12) 0.003
Ever overdosed (yes vs. no) 1.41 (0.73–2.77) 0.314 0.76 (0.32–1.76) 0.522
Unable to access addiction treatmenta (yes vs. no) 3.29 (1.20–11.58) 0.035 3.41 (1.02-14.10) 0.062
Drug or alcohol treatmenta (yes vs. no) 2.00 (1.03–3.91) 0.041 1.71 (0.71–4.19) 0.235
CI confidence interval
aIn the last 6 months
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overdose [24], further suggesting that PWUD tend to
underestimate their risk of personal overdose and may
also be underestimating their risk of witnessing an over-
dose. It is also possible that some youth did not participate
in the THN program due to perceived ineligibility (at the
time of data collection only individuals considered high-
risk for witnessing or experiencing an overdose received
free kit following administration training), though this is
unlikely due to the high-risk study population, as well as
the high rates of non-fatal overdose among this sample of
youth. Nolan et al.’s [22] study of adult PWUD identified
even lower rates of THN possession (13%) than those re-
ported in our sample of young PWUD (22.5%). This may
partially be explained by the fact that naloxone distribu-
tion increased significantly in 2016; Nolan et al.’s [22]
study used data from 2014 to 2015 only, while the current
study included data from participants who completed a
questionnaire in 2016. However, it is also worth noting
that Vancouver’s THN program targeted youth through
the distribution of THN in emergency departments as
well as youth-centered promotional activities [25], which
may have contributed to higher rates of uptake among
youth.
Public injection, heroin use, and methamphetamine
use have all been associated with non-fatal overdose
[26, 27] and were also associated with THN knowledge
or possession in the present study. This may suggest that
certain forms of high-intensity drug use can prompt THN
participation. The present study also found that cocaine
or crack use was negatively associated with THN know-
ledge, which could be explained by a lower perceived risk
of opioid-related overdose among people who use crack
or cocaine when compared to people who use opioids. Be-
cause naloxone only reverses the effects of opioid-related
overdoses (and not overdoses caused by cocaine or crack),
naloxone kit acquisition may seem irrelevant to youth who
do not use opioids daily. However, all street-involved youth
are at risk of witnessing an overdose due to the high rates
of daily opioid use and non-fatal overdose in their environ-
ment [28], and one study of youth who inject drugs found
that “speedball” (a mixture of heroin and cocaine) use was
associated with an increased risk of overdose [29]. In
addition, fentanyl-detected deaths in B.C. often involve the
use of other illicit drugs [2], though it remains unclear what
proportion of these deaths can be attributed to fentanyl
contamination and polysubstance use. As such, all street-
involved youth who use illicit drugs would be important
THN owners, and youth who use cocaine or crack may
benefit from targeted educational and marketing efforts to
increase THN participation.
A recent meta-analysis found male gender to be one of
the factors most strongly associated with drug overdose
death [30], and in B.C., males accounted for 83% of all
illicit drug overdose deaths from January to September
2017 [2]. However, male gender was negatively associated
with THN ownership in the current study. This highlights
the need to target male youth in THN programs, who
may face sociocultural barriers to accessing THN
Table 3 Bivariate and multivariate logistic regression analyses of factors associated with ownership of THN
Characteristics Unadjusted Adjusted
Odds ratio
(95% CI)
p value Odds ratio
(95% CI)
p value
Age (per year younger) 1.04 (0.90–1.20) 0.610 1.05 (0.88–1.25) 0.627
Gender (male vs. female) 0.27 (0.13–0.57) 0.001 0.29 (0.11–0.72) 0.008
White ethnicity (yes vs. no) 2.68 (1.27–5.99) 0.012 2.51 (1.02–6.51) 0.049
Downtown Eastside residencea (yes vs. no) 0.63 (0.25–1.43) 0.289 0.38 (0.11–1.14) 0.097
Ever homeless (yes vs. no) 1.19 (0.41–4.35) 0.768 1.25 (0.31–6.00) 0.767
High school completion (yes vs. no) 1.14 (0.56–2.32) 0.714 1.37 (0.54–3.54) 0.508
Employmenta (yes vs. no) 1.05 (0.45–2.32) 0.906 1.23 (0.44–3.31) 0.685
Incarcerationa (yes vs. no) 1.02 (0.35–2.62) 0.963 0.80 (1.19–2.96) 0.748
Daily heroin usea (yes vs. no) 3.57 (1.70–7.54) 0.001 3.08 (1.09–9.11) 0.036
Daily cocaine or crack usea (yes vs. no) 0.36 (0.02–2.03) 0.346 0.25 (0.01–2.43) 0.295
Daily methamphetamine usea (yes vs. no) 2.43 (1.15–5.09) 0.019 2.99 (1.13–8.13) 0.028
Daily use of prescription opioidsa (yes vs. no) 0.29 (0.02–1.58) 0.248 0.20 (0.01–1.36) 0.161
Public injectinga (yes vs. no) 2.53 (1.23–5.29) 0.012 1.55 (0.55–4.32) 0.403
Ever overdosed (yes vs. no) 1.23 (0.61–2.50) 0.566 0.63 (0.24–1.58) 0.336
Unable to access addiction treatmenta (yes vs. no) 0.94 (0.35–2.28) 0.899 0.77 (0.22–2.47) 0.671
Drug or alcohol treatmenta (yes vs. no) 1.85 (0.89–3.98) 0.106 1.47 (0.58–3.82) 0.419
CI confidence interval
aIn the last 6 months
Goldman-Hasbun et al. Harm Reduction Journal  (2017) 14:79 Page 5 of 7
programs not experienced by male adult PWUD. There is
in fact evidence that male adolescents and young adults
are less likely than their female counterparts to access
health services due to stigma, as well as gender, social, and
cultural norms [31, 32]. The same meta-analysis also
found Caucasian/white ethnicity to be positively associ-
ated with drug overdose death [30]. In the present study,
Caucasian/white ethnicity was positively associated with
both knowledge and possession of THN, which is consist-
ent with what has been found in the literature of adult
PWUD [22]. However, in B.C., First Nations individuals
are at increased risk of fatal overdose compared to the
general population [33]. First Nations individuals, and
other non-white individuals who may be more vulnerable
to overdose, may then also benefit from targeted strategies
to improve their access to THN.
There are limitations to this study. First, because this
is a cross-sectional study, we are unable to infer caus-
ation. Second, because there are no registries of street
youth to draw upon, our sample was not randomly
selected and therefore may not be representative of all
street youth in Vancouver. However, we note that the
characteristics of the ARYS sample are similar to those
from other studies of high-risk youth [34–36]. Third, we
relied on self-report, which may have been subject to
response biases, including recall bias and socially desir-
able responding, though we know of no reason why this
would explain the associations we identified in this
study. Fourth, due to our smaller sample size, we were
not able to include data related to witnessed overdose
and naloxone administration, which may have influenced
the results of our multivariate analyses. We also did not
ask youth about their reasons for not owning kits, or
whether those who reported THN possession carried the
kits with them. Lastly, our study included pre-2016 data,
after which THN distribution increased significantly.
Our results demonstrate an increase in THN uptake that
parallels the program’s expansion; however, current rates
of THN uptake may be continuing to rise.
Conclusions
To our knowledge, this is the first study to examine
sociodemographic characteristics and substance use-
related factors of street-involved youth who are familiar
with and have acquired THN kits and the first to evalu-
ate the rates of knowledge and possession of THN in
this population. The findings of the present study high-
light the need to increase knowledge of and access to
THN among all street-involved youth who use illicit
drugs, particularly among local populations found to
be among the highest risk of fatal overdose. Specifically,
these findings suggest that males, people who do not
identify as “Caucasian/white,” and people who use
crack or cocaine would benefit from targeted
approaches to improve their access to THN programs.
Future research should focus on examining interven-
tions that aim to address barriers to THN acquisition
among those currently underrepresented in THN
programs.
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